The prognostic impact of CD163-positive macrophages in follicular Lymphoma: A study from the BC cancer agency and the lymphoma study association

Clinical Cancer Research

Volumn 21, Issue 15, 2015, Pages 3428-3435

  Kridel, Robert ^a   Xerri, Luc ^b   Gelas Dore, Bénédicte ^c   Tan, King ^a   Feugier, Pierre ^d   Vawda, Ayesha ^a   Canioni, Danielle ^e   Farinha, Pedro ^a   Boussetta, Sami ^c   Moccia, Alden A ^a   Brice, Pauline ^f   Chavez, Elizabeth A ^a   Kyle, Alastair H ^a   Scott, David W ^a   Sanders, Ashley D ^g   Fabiani, Bettina ^h   Slack, Graham W ^a   Minchinton, Andrew I ^a   Haioun, Corinne ⁱ   Connors, Joseph M ^a   Sehn, Laurie H ^a   Steidl, Christian ^a   Gascoyne, Randy D ^a   Salles, Gilles ^j   more..

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b INSTITUT PAOLI CALMETTES   (France)

^c CENTRE HOSPITALIER LYON SUD   (France)

^d UNIVERSITY HOSPITAL OF NANCY   (France)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f SAINT LOUIS HOSPITAL   (France)

^g BRITISH COLUMBIA CANCER AGENCY   (Canada)

^h HÔPITAL SAINT ANTOINE   (France)

ⁱ HENRI MONDOR HOSPITAL   (France)

^j UNIVERSITÉ LYON 1   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD163 ANTIGEN; CD68 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE; CD68 ANTIGEN, HUMAN; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN;

ADULT; ADVERSE OUTCOME; ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CELL INFILTRATION; CLINICAL OBSERVATION; CONTROLLED STUDY; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; HUMAN TISSUE; MACROPHAGE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SYSTEMIC THERAPY; AGED; BIOSYNTHESIS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFECTS; GENETICS; LYMPHOMA, FOLLICULAR; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TISSUE MICROARRAY; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; MACROPHAGES; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, CELL SURFACE; RITUXIMAB; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT; VINCRISTINE;

EID: 84939831345     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-3253     Document Type: Article

References (32)

1. Bachy E, Houot R, Morschhauser F, Sonet A, Brice P, Belhadj K, et al. Longterm follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma. Haematologica 2013;98:1107-14.
2. Ghielmini M, Vitolo U, Kimby E, Montoto S, Walewski J, Pfreundschuh M, et al. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol 2013;24:561-76.
3. Kridel R, Sehn LH, Gascoyne RD. Pathogenesis of follicular lympho ma. J Clin Invest 2012;122:3424-31.
4. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004;351: 2159-69.
5. Farinha P, Masoudi H, Skinnider BF, Shumansky K, Spinelli JJ, Gill K, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005;106:2169-74.
6. Alvaro T, Lejeune M, Camacho FI, Salvado MT, Sanchez L, García JF, et al. The presence of STAT1-positive tumor-associated macrophages and their relation to outcome in patients with follicular lymphoma. Haematologica 2006;91:1605-12.
7. Canioni D, Salles G, Mounier N, Brousse N, Keuppens M, Morchhauser F, et al. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol 2008;26:440-6.
8. Byers RJ, Sakhinia E, Joseph P, Glennie C, Hoyland JA, Menasce LP, et al. Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling. Blood 2008;111:4764-70.
9. Coiffier B, Li W, Henitz ED, Karkera JD, Favis R, Gaffney D, et al. Pre-specified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab. Clin Cancer Res 2013;19:2551-61.
10. Clear AJ, Lee AM, Calaminici M, Ramsay AG, Morris KJ, Hallam S, et al. Increased angiogenic sprouting in poor prognosis FL is associated with elevated numbers of CD163 +macrophages within the immediate sprouting microenvironment. Blood 2010;115:5053-6.
11. Taskinen M, Karjalainen-Lindsberg ML, Nyman H, Eerola L-M, Leppä S. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin Cancer Res 2007;13:5784-9.
12. De Jong D, Koster A, Hagenbeek A, Raemaekers J, Veldhuizen D, Heisterkamp S, et al. Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols. Haematologica 2009;94:70-7.
13. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 2012;122:787-95.
14. Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. Nature 2013;496:445-55.
15. Guilloton F, Caron G, Ménard C, Pangault C, Ame-Thomas P, Dulong J, et al. Mesenchymal stromal cells orchestrate follicular lymphoma cell niche through the CCL2-dependent recruitment and polarization of monocytes. Blood 2012;119:2556-67.
16. Epron G, Ame-Thomas P, Le Priol J, Pangault C, Dulong J, Lamy T, et al. Monocytes and T cells cooperate to favor normal and follicular lymphoma B-cell growth: role of IL-15 and CD40L signaling. Leukemia 2012;26: 139-48.
17. Buechler C, Ritter M, Orso E, Langmann T, Klucken J, Schmitz G. Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and antiinflammatory stimuli. J Leukoc Biol 2000;67: 97-103.
18. Salles G, Seymour JF, Offner F, Lopez-Guillermo A, Belada D, Xerri L, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial. Lancet 2011; 377:42-51.
19. Tan KL, Scott DW, Hong F, Kahl BS, Fisher RI, Bartlett NL, et al. Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood 2012;120:3280-7.
20. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004;10:7252-9.
21. Sander B, de Jong D, Rosenwald A, Xie W, Balague O, Calaminici M, et al. The reliability of immunohistochemical analysis of the tumor microenvironment in follicular lymphoma: a validation study from the Lunenburg Lymphoma Biomarker Consortium. Haematologica 2014;99: 715-25.
22. Harris JA, Jain S, Ren Q, Zarineh A, Liu C, Ibrahim S. CD163 versus CD68 in tumor associated macrophages of classical Hodgkin lymphoma. Diagn Pathol 2012;7:12.
23. Klein JL, Nguyen TT, Bien-Willner GA, Chen L, Foyil K V, Bartlett NL, et al. CD163 immunohistochemistry is superior to CD68 in predicting outcome in classical Hodgkin lymphoma. Am J Clin Pathol 2014;141: 381-7.
24. Pulford KA, Sipos A, Cordell JL, Stross WP, Mason DY. Distribution of the CD68 macrophage/myeloid associated antigen. Int Immunol 1990; 2:973-80.
25. De Palma M, Lewis CE. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 2013;23:277-86.
26. Koh YW, Park C-S, Yoon DH, Suh C, Huh J. CD163 expression was associated with angiogenesis and shortened survival in patients with uniformly treated classical Hodgkin lymphoma. PLoS One 2014;9: e87066.
27. Mantovani A, Polentarutti N, Luini W, Peri G, Spreafico F. Role of host defense mechanisms in the antitumor activity of adriamycin and daunomycin in mice. J Natl Cancer Inst 1979;63:61-6.
28. Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 2013;38: 729-41.
29. Maloney DG. Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med 2012;366:2008-16.
30. Minard-Colin V, Xiu Y, Poe JC, Horikawa M, Magro CM, Hamaguchi Y, et al. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. Blood 2008;112:1205-13.
31. Pallasch CP, Leskov I, Braun CJ, Vorholt D, Drake A, Soto-Feliciano YM, et al. Sensitizing protective tumor microenvironments to antibody-mediated therapy. Cell 2014;156:590-602.
32. Leidi M, Gotti E, Bologna L, Miranda E, Rimoldi M, Sica A, et al. M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. J Immunol 2009;182:4415-22.